Biolidics Limited - ANNOUNCEMENTS

19 Dec 2019

Change Of Company Secretary

26 Nov 2019

Biolidics And Sysmex Deepens Collaboration With Definitive Agreement

15 Nov 2019

Change In Corporate Information - Change Of Registered Office

11 Nov 2019

Biolidics' partner in China to launch commercial LDT service of PD-L1

04 Nov 2019

Biolidics' Clearcell FX1 System Obtains Approval In China

25 Sep 2019

Resignation of Executive Director and Chief Executive Officer

17 Sep 2019

Incorporation Of Wholly-owned Subsidiary In Australia

10 Sep 2019

Biolidics To Collaborate With A*Star's Genome Institute Of Singapore

09 Sep 2019

Collaboration With Hangzhou Normal University To Undertake Clinical Investigations

27 Aug 2019

Biolidics Accorded The Prestigious "IPOS Award For IP Champions " By WIPO-IPOS

20 Aug 2019

Appointment of Chief Commercial Officer

08 Aug 2019

CGS - CIMB: Add Call And S$0 .32 Target Price Are Intact For This Under - Covered Company

07 Aug 2019

Financial Statements And Related Announcement - Half Yearly Results

02 Aug 2019

Incorporation Of Wholly - Owned Subsidiary In The People 's Republic Of China

18 Jul 2019

Appointment Of Chief Operating Officer

02 Jul 2019

Request For Lifting Of Trading Halt - Sponsor Statement

02 Jul 2019

Request for Lifting of Trading Halt

02 Jul 2019

Clarification Of Press Release On 1 July 2019 And Revised Press Release

01 Jul 2019

LDT By Biolidics' Partner To Be Reimbused In China

25 Jun 2019

Biolidics To Broaden Its Presence In China 's Cancer Diagnostics Market With New Partnership

14 Jun 2019

Resignation of Chief Operating Officer

14 May 2019

Biolidics Enters Into Another Partnership In China To Develop New Commercial Applications Using Biolidics ClearCell® FX1 System And CTChip® FR1 Biochips

30 Apr 2019

Annual General Meeting - Presentation Slides

30 Apr 2019

Annual General Meeting - Voluntary

12 Apr 2019

Annual Reports and Related Documents

12 Apr 2019

Annual General Meeting

29 Mar 2019

Biolidics ' Laboratory Partner In China To Offer Laboratory - Developed Cancer Tests Using Biolidics ' ClearCell® FX1 System And CTChip® FR1 Biochips

01 Mar 2019

Financial Statements and Related Announcement - Full Yearly Results

01 Mar 2019

Biolidics Achieves Improved Performance In FY2018; Focus On New Clinical And Commercial Applications With Its Disruptive, Patented Medical Technology

20 Feb 2019

Biolidics Enters Into a Strategic collaboration With Sysmex Corporation

20 Feb 2019

Signing of Non - Binding Term Sheet With Sysmex Corporation

15 Jan 2019

Biolidics ' Strategic Shareholder, Professor Xie Tian, Voluntarily Subjects His Remaining Stake In Biolidics To A Moratorium